{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:53:35Z","timestamp":1790942015714,"version":"4.1.0"},"reference-count":1,"publisher":"S. Karger AG","issue":"2-3","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestion"],"published-print":{"date-parts":[[2003]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; In neuroendocrine tumors, metastases are a negative prognostic factor for survival and quality of life. Transcatheter arterial chemoembolization (TACE) is thought to be an effective symptomatic and antiproliferative treatment in patients with otherwise progressive disease. &lt;i&gt;Methods:&lt;\/i&gt; 62 chemoembolization procedures in 26 patients with progressive neuroendocrine tumors were reviewed. The underlying disease was carcinoid syndrome in 10, non-functional midgut tumor in 2, non-functional pancreatic tumor in 7, malignant insulinoma in 2 patients, non-functional tumor of the stomach in 1 and of unknown origin in 4 patients. Tumor burden of the liver was &lt;25% in 3, 25\u201350% in 11, 50\u201375% in 6 and &gt;75% in 6 patients. &lt;i&gt;Results:&lt;\/i&gt; TACE was technically successful in 57 cases. Four patients developed minor and 5 major complications. The 30-day mortality rate was 7.7%. According to WHO criteria, 14 patients had no change in tumor burden, 2 had regression and 5 progress after chemoembolization. Patients with a tumor burden &gt;75% of the liver did not benefit from TACE due to the development of major complications, whereas patients with low (&lt;50%) tumor burden and high (&gt;50%) lipiodol uptake showed a trend towards longer survival. Five-year survival time after diagnosis was 48%. Patients treated with octreotide and\/or \u03b1-interferon had no benefit from chemoembolization with regard to their carcinoid syndrome. &lt;i&gt;Conclusions:&lt;\/i&gt; In this retrospective study, patients with low (&lt;50%) tumor burden and high (&gt;50%) lipiodol uptake responded better to TACE than end-stage patients.<\/jats:p>","DOI":"10.1159\/000074522","type":"journal-article","created":{"date-parts":[[2003,10,31]],"date-time":"2003-10-31T15:06:34Z","timestamp":1067612794000},"page":"94-101","source":"Crossref","is-referenced-by-count":122,"title":["Transarterial Chemoembolization of Advanced Liver Metastases of Neuroendocrine Tumors \u2013 A Retrospective Single-Center Analysis"],"prefix":"10.1159","volume":"68","author":[{"given":"O.","family":"Kress","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-J.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Klose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Alfke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2004,1,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s002709900391"}],"container-title":["Digestion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/74522","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/74522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:53:34Z","timestamp":1745466814000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000074522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":1,"journal-issue":{"issue":"2-3","published-online":{"date-parts":[[2003,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000074522","archive":["Portico"],"relation":{},"ISSN":["0012-2823","1421-9867"],"issn-type":[{"value":"0012-2823","type":"print"},{"value":"1421-9867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003]]}}}